Company / Interest Expense
Myriad Genetics, Inc. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$2.9M
FY2023
5-year range
$2.9M / $6.6M
FY2019-FY2023
Trend
-9.4%
vs FY2022
Sector context
#36 of 44
Health Care
What the data says
Myriad Genetics, Inc.'s interest expense of $3M is lower than 82% of companies in the Health Care sector (FY2023). Interest Expense has declined for 3 consecutive years, from $11M in FY2020 to $3M in FY2023.
Based on SEC 10-K filings.
$3M in FY2023 with a 5-year CAGR of -1.9%.
Improved from $7M to $3M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -35.5%
- 5-Year CAGR
- -1.9%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 44This company $2.9M Sector average $291.0M
▼
-99.0% below sector average
Key checks
Key Insights
- Myriad Genetics, Inc.'s interest expense has declined for 3 consecutive years.
- 5-year CAGR of -1.9%, indicating a declining trend.
- In FY2023, interest expense decreased 9.4% year-over-year.
- Ranks #36 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $2.9M | -9.4% |
| FY2022 | $3.2M | -51.5% |
| FY2021 | $6.6M | -38.9% |
| FY2020 | $10.8M | +80.0% |
| FY2019 | $6.0M | +87.5% |
| FY2018 | $3.2M | -46.7% |
| FY2017 | $6.0M | +1900.0% |
| FY2016 | $300.0K | +50.0% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026